BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.
Researchers evaluated BPC-157 and two newly designed hybrid peptide analogs (CIARA-1 and CIARA-2) as competitive inhibitors of acetylcholinesterase, an enzyme target in Alzheimer’s disease management. All three compounds showed reversible competitive inhibition, with the hybrid analogs demonstrating superior potency compared to native BPC-157. While the peptides are significantly less potent than approved AChE inhibitors, the study validates BPC-157 as a viable scaffold for developing multifunctional neurodegenerative therapeutics through rational structural modification.
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. Read Post »